NMRD - Nemaura Medical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.2600
+0.2400 (+7.95%)
As of 11:58AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.0200
Open3.2500
Bid3.2600 x 2200
Ask3.3700 x 800
Day's Range3.1000 - 3.3800
52 Week Range2.5000 - 14.8000
Volume2,931
Avg. Volume7,940
Market Cap67.835M
Beta (5Y Monthly)0.47
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Nemaura Medical Reports Results and Provides Business Update for the Third Quarter Ended December 31, 2019

    The Company announced a partnership with the award-winning UK-based company, Changing Health, to bring digital behavior programs to improve the management, reversal and prevention of Type 2 diabetes in multiple territories commencing with the United Kingdom and Ireland. Changing Health is a provider of digital coaching services to the National Health Service England, aimed at the prevention or reversal of Type 2 diabetes.

  • GlobeNewswire

    Nemaura Provides 2019 Year-End Corporate Update

    Loughborough, England, Dec. 20, 2019 (GLOBE NEWSWIRE) --  Nemaura Medical, Inc. (NMRD), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a 2019 year-end corporate update. The company started the first phase of our commercial launch of sugarBEAT® in the United Kingdom with the first shipments of sugarBEAT® CGM devices to diabetic and pre-diabetic patients from whom positive user feedback has been received.

  • GlobeNewswire

    Nemaura Medical and Changing Health announce Partnership to provide award-winning Diabetes Behavioral Change services

    Loughborough, England, Dec. 17, 2019 --   Nemaura Medical, Inc. (NASDAQ:NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible.

  • GlobeNewswire

    Nemaura Medical announces expansion of SugarBEAT® offering  with BEAT® Diabetes digital subscription services

    Loughborough, England, Dec. 05, 2019 --  Nemaura Medical, Inc. (NASDAQ:NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a.

  • GlobeNewswire

    Nemaura Medical Announces 1 for 10 Reverse Split Intended to Attract a Wider Universe of Institutional Investors

    The reverse split is expected to take effect at the market open on December 5, 2019. In accordance with the reverse split, each stockholder’s percentage ownership interest in Nemaura Medical remains unchanged. Any fractional shares resulting from the reverse stock split were rounded up to the nearest whole share of common stock.

  • GlobeNewswire

    Nemaura Medical Reports Results and Provides Business Update for the Second Quarter Ended September 30, 2019

    Loughborough, England, Nov. 11, 2019 (GLOBE NEWSWIRE) --  – Nemaura Medical, Inc. (NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today reported financial results for the second quarter ended September 30, 2019. Dr. Faz Chowdhury, CEO of Nemaura commented, “This has been an exciting period for Nemaura as we officially commenced the commercial rollout plans for SugarBEAT® following our recent CE approval. As the world’s first non-invasive, safe, needle-free CGM, SugarBEAT® is uniquely positioned to target the underserved $80 billion market for Type 2 diabetics and pre-diabetics.

  • GlobeNewswire

    Nemaura Medical Provides Update Regarding Commercial Launch of SugarBEAT® and First Patient User Experiences as Presented at EASD Symposia 2019 in Barcelona

    Loughborough, England, Oct. 03, 2019 (GLOBE NEWSWIRE) --  Nemaura Medical, Inc. (NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today provided an update regarding the commercial launch of SugarBEAT® and feedback from its first patient user experiences as presented at the recent symposia hosted by Nemaura  at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona. Dr. Faz Chowdhury, Chief Executive Officer, discussed key milestones in the development and plans for the commercial rollout program for SugarBEAT® in the UK, Ireland, Germany and other key European markets following its recent CE mark approval in the European Union.

  • GlobeNewswire

    Nemaura Medical to Hold a Symposia at EASD in Barcelona on Thursday September 19, 2019

    Loughborough, England , Sept. 12, 2019 -- Loughborough, England – September 12, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on.

  • GlobeNewswire

    Nemaura Medical Reports Quarterly Results for First Quarter Ended June 30, 2019

    Loughborough, England, Aug. 09, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today reported financial results for the first quarter ended June 30, 2019. The credit facility is at 8% interest, with interest payments due quarterly and principal due in full at maturity in five years.  The credit facility has no stock, warrants, or equity related instruments, or other associated expenses. With adequate cash on hand and the credit facility, along with anticipated revenue, Management has instructed Maxim to suspend all ATM activities.

  • GlobeNewswire

    Nemaura Medical Announces First Shipments of SugarBEAT® Devices to Diabetic and Pre-Diabetic Patients as Part of its First Phase of Launch

    Loughborough, England, Aug. 07, 2019 (GLOBE NEWSWIRE) --  Nemaura Medical, Inc. (NMRD), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced the first shipments of SugarBEAT® to diabetic and pre-diabetic patients in the United Kingdom. Nemaura Medical will present data from its first users as part of several presentations planned at a symposium being held by the Company at the European Association for the Study of Diabetes (EASD) conference in Barcelona on September 19, 2019.

  • GlobeNewswire

    Nemaura Medical Inc. Announces $8 million Senior Debt Facility Provided by Existing Investors

    Loughborough, England, Aug. 01, 2019 (GLOBE NEWSWIRE) --  Nemaura Medical, Inc. (NMRD), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced an $8 million (USD) senior credit facility from existing major shareholders, with the first $3.5 million available immediately, to help fund the Company’s European commercial launch plans.  The non-dilutive credit facility will carry 8% interest with quarterly payments and the principal due only upon maturity in 5 years.  The credit facility has no stock, warrants, or equity related instruments, or other associated expenses. Dr. Faz Chowdhury, CEO of Nemaura, stated, “Nemaura is at an exciting inflection point, having recently received CE Mark approval for SugarBEAT®, the world’s first non-invasive, needle-free, continuous glucose monitor.  We recently submitted a De Novo 510(k) medical device application to the U.S. Food and Drug Administration for SugarBEAT®.

  • GlobeNewswire

    Nemaura Medical Inc. Appoints Chris Avery as Vice President of Global Business Operations to Support Global Commercial Launch of SugarBEAT®

    Loughborough, England , July 18, 2019 --  Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive,.

  • GlobeNewswire

    Nemaura Medical Inc. Submits De Novo 510(k) Application for SugarBEAT® to the U.S. Food and Drug Administration

    Loughborough, England , July 10, 2019 --  Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive,.

  • GlobeNewswire

    Nemaura Provides Fiscal 2019 Year-End Business Update

    Nemaura Medical, Inc. (NMRD), a medical technology company commercializing SugarBEAT®, a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today provided a business update for the fiscal year ending March 31, 2019 and reported on recent corporate developments.

  • GlobeNewswire

    Nemaura Medical Interview to Air on Bloomberg International on the RedChip Money Report

    Loughborough, England, June 14, 2019 --  – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive,.

  • GlobeNewswire

    Nemaura Announces CE Mark Approval of SugarBEAT®

    Loughborough,England, May 29, 2019 -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable.

  • GlobeNewswire

    Nemaura Announces Open-Source Software for its Continuous Glucose Monitor SugarBEAT®

    Loughborough, England , May 02, 2019 (GLOBE NEWSWIRE) --  – Nemaura Medical, Inc. (NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced it will allow  third-party applications, such as diabetes management, exercise and nutrition focused apps royalty free  access to SugarBEAT® CGM app data. As a result, users will be able to directly access SugarBEAT® generated glucose data through their preferred participating mobile aplications, empowering users with greater choice over when to use this data to better understand how food choices and other lifestyle factors impact glucose levels.

  • GlobeNewswire

    Nemaura Announces Successful Completion of Summative Human Factors Usability Study for SugarBEAT®

    Nemaura Medical, Inc. (NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has successfully completed two summative human factors usability studies for SugarBEAT®.  The usability studies were conducted according to the U.S. Food and Drug Administration (FDA) guidance on ‘Applying Human Factors and Engineering to Medical Devices,’ in preparation for submission of its medical device application to the FDA for SugarBEAT®.

  • GlobeNewswire

    Nemaura Announces Addition of New Predictive Alert Functionality to SugarBEAT®

    Loughborough, England , April 16, 2019 -- April 16, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as.

  • GlobeNewswire

    Nemaura CEO Provides Update to Shareholders

    Loughborough, England, March 28, 2019 -- Loughborough, England – March 28, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the.

  • GlobeNewswire

    Nemaura Medical Announces Exclusive License and Supply Agreement for SugarBEAT® in the GCC Region

    Loughborough, England – March 12, 2019 – Nemaura Medical, Inc. (NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has signed an exclusive license and supply agreement for SugarBEAT® with TPMENA in the Gulf Cooperation Council (GCC) Region, which includes Bahrain, Kuwait, Saudi Arabia, Oman and United Arab Emirates. TPMENA is a distributor of medical devices in the GCC Region, backed by Cigalah group.